Michael Coyle
Director/Board Member at HAEMONETICS CORPORATION
Net worth: 895 663 $ as of 2024-03-30
Profile
Mr. Michael J. Coyle is a President, Chief Executive Officer & Director at iRhythm Technologies, Inc., an Independent Director at Haemonetics Corp., a President at HeartWare International, Inc., an EVP, Group President-Cardiac & Vascular Group at Medtronic, Inc., a Chief Executive Officer at Medtronic 3F Therapeutics, Inc. and a Chief Executive Officer at Medtronic ATS Medical, Inc. He is on the Board of Directors at iRhythm Technologies, Inc. and Haemonetics Corp. Mr. Coyle was previously employed as a Group President-Cardiac & Vascular Group by Medtronic Plc, an Independent Director by Volcano Corp., a President & Chief Operating Officer by Daig Corp., a President-Cardiac Rhythm Management Division by St. Jude Medical LLC, and a Principal by Eli Lilly & Co. He also served on the board at VNUS Medical Technologies, Inc. He received his undergraduate degree from Case Western Reserve University and an MBA from The Wharton School of the University of Pennsylvania.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
HAEMONETICS CORPORATION
0.02% | 2023-08-03 | 10,494 ( 0.02% ) | 895 663 $ | 2024-03-30 |
Michael Coyle active positions
| Companies | Position | Start |
|---|---|---|
| HAEMONETICS CORPORATION | Director/Board Member | 2020-04-15 |
Medtronic ATS Medical, Inc.
 Medtronic ATS Medical, Inc. Medical SpecialtiesHealth Technology Medtronic ATS Medical, Inc. develops, manufactures and markets medical devices for the treatment of structural heart disease. The company was founded on November 09, 2000 and is headquartered in Minneapolis, MN. | Chief Executive Officer | - |
Medtronic 3F Therapeutics, Inc.
 Medtronic 3F Therapeutics, Inc. Medical SpecialtiesHealth Technology Medtronic 3F Therapeutics, Inc. develops, manufactures and markets cardiovascular devices. The company is headquartered in Minneapolis, MN. | Chief Executive Officer | - |
Baropace, Inc.
 Baropace, Inc. Electronic Equipment/InstrumentsElectronic Technology Baropace, Inc. is a privately held medical device company located in Ashland, OR. Baropace is focused on the development of pressurepace™, a real-time physiologic control software and hardware to regulate cardiac pacemakers to treat resistant hypertension and heart failure with preserved ejection fraction (hfpef). The company has proprietary biotechnologies including a pacemaker control algorithm (pressurepace™) and new sensor technologies working through patient mobile and wearable platforms. Baropace expects to launch a first-in-human clinical trial (relievehtn-i) in the fourth quarter of 2022. Pressurepace™ is limited by federal law to investigational use only and is not approved for sale in any geography. The company was founded in 2019 by Eli Gang and Michael Burnam, who has been the CEO since 2018. | Director/Board Member | - |
Former positions of Michael Coyle
| Companies | Position | End |
|---|---|---|
| IRHYTHM TECHNOLOGIES, INC. | Chief Executive Officer | 2021-05-31 |
Medtronic, Inc.
 Medtronic, Inc. Medical SpecialtiesHealth Technology Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN. | Corporate Officer/Principal | 2020-12-31 |
| MEDTRONIC PLC | Corporate Officer/Principal | 2020-12-30 |
VNUS Medical Technologies, Inc.
 VNUS Medical Technologies, Inc. Medical SpecialtiesHealth Technology VNUS Medical Technologies, Inc. provides medical devices and procedures for the minimally invasive treatment of venous reflux disease, an underlying cause of varicose veins. Venous reflux disease results in symptoms such as leg pain, swelling, fatigue, skin ulcers, and painful varicose veins. The company was founded on January 31, 1995 and is headquartered in San Jose, CA. | Director/Board Member | 2009-06-16 |
| ST JUDE MEDICAL INC | Corporate Officer/Principal | 2007-12-30 |
Training of Michael Coyle
| Case Western Reserve University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| HAEMONETICS CORPORATION | Health Technology |
| IRHYTHM TECHNOLOGIES, INC. | Health Technology |
| MEDTRONIC PLC | Health Technology |
| Private companies | 9 |
|---|---|
Daig Corp.
 Daig Corp. Medical SpecialtiesHealth Technology Part of Abbott Laboratories, Daig Corp. is a private company that manufactures specialty catheters. The company is based in Hopkins, MN. Daig was acquired by St. Jude Medical LLC, part of Abbott Laboratories from January 05, 2017 on May 31, 1996 for $439.60 million. | Health Technology |
Medtronic, Inc.
Medtronic, Inc. Medical SpecialtiesHealth Technology Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN. | Health Technology |
St. Jude Medical LLC
 St. Jude Medical LLC Medical SpecialtiesHealth Technology St. Jude Medical LLC develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The company was founded by Manuel A. Villafana in 1976 and is headquartered in St. Paul, MN. | Health Technology |
Medtronic ATS Medical, Inc.
Medtronic ATS Medical, Inc. Medical SpecialtiesHealth Technology Medtronic ATS Medical, Inc. develops, manufactures and markets medical devices for the treatment of structural heart disease. The company was founded on November 09, 2000 and is headquartered in Minneapolis, MN. | Health Technology |
VNUS Medical Technologies, Inc.
VNUS Medical Technologies, Inc. Medical SpecialtiesHealth Technology VNUS Medical Technologies, Inc. provides medical devices and procedures for the minimally invasive treatment of venous reflux disease, an underlying cause of varicose veins. Venous reflux disease results in symptoms such as leg pain, swelling, fatigue, skin ulcers, and painful varicose veins. The company was founded on January 31, 1995 and is headquartered in San Jose, CA. | Health Technology |
Philips Image Guided Therapy Corp.
 Philips Image Guided Therapy Corp. Medical SpecialtiesHealth Technology Volcano Corp. designs, develops and manufactures a broad suite of intravascular ultrasound products. The company was founded by Olav B. Bergheim and Samuel Ward Casscells and is headquartered in San Diego, CA. | Health Technology |
HeartWare International LLC
 HeartWare International LLC Medical SpecialtiesHealth Technology HeartWare International LLC is a medical device company, which engaged in the development and manufacturing of miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The company was founded on July 29, 2008 and is headquartered in Framingham, MA. | Health Technology |
Medtronic 3F Therapeutics, Inc.
Medtronic 3F Therapeutics, Inc. Medical SpecialtiesHealth Technology Medtronic 3F Therapeutics, Inc. develops, manufactures and markets cardiovascular devices. The company is headquartered in Minneapolis, MN. | Health Technology |
Baropace, Inc.
Baropace, Inc. Electronic Equipment/InstrumentsElectronic Technology Baropace, Inc. is a privately held medical device company located in Ashland, OR. Baropace is focused on the development of pressurepace™, a real-time physiologic control software and hardware to regulate cardiac pacemakers to treat resistant hypertension and heart failure with preserved ejection fraction (hfpef). The company has proprietary biotechnologies including a pacemaker control algorithm (pressurepace™) and new sensor technologies working through patient mobile and wearable platforms. Baropace expects to launch a first-in-human clinical trial (relievehtn-i) in the fourth quarter of 2022. Pressurepace™ is limited by federal law to investigational use only and is not approved for sale in any geography. The company was founded in 2019 by Eli Gang and Michael Burnam, who has been the CEO since 2018. | Electronic Technology |
- Stock Market
- Insiders
- Michael Coyle
